Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 2;13:1130852. doi: 10.3389/fonc.2023.1130852

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Torchiaro, Petti, Arena, Sassi, Migliardi, Mellano, Porporato, Basiricò, Gammaitoni, Berrino, Montone, Corti, Crisafulli, Marchiò, Bardelli and Medico

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vivo efficacy of pevonedistat and bortezomib. (A) In vivo growth of three PDX cohorts (n=5), treated for four weeks respectively with vehicle, bortezomib (0.5mg/kg) and pevonedistat (90mg/kg). (B) T-test p-values comparing tumor size in the vehicle cohort vs. the bortezomib or pevonedistat cohort, at different treatment times. (C, D) Kaplan-Meier survival plots comparing the vehicle cohort vs the bortezomib (C) or pevonedistat (D) cohorts. P-values are from Longrank test analysis. (E) Representative pictures of IHC staining for Ki67 after PDX treatment with vehicle, bortezomib and pevonedistat, at the end of the experiment.